阿法骨化醇冲击治疗在血液透析并继发性甲状旁腺功能亢进的应用被引量：1

下载PDF

导出

摘要目的:观察阿法骨化醇冲击治疗在维持性血液透析并继发性甲状旁腺功能亢进患者的应用效果。方法:将60例血液透析并继发性甲状旁腺功能亢进患者随机均分为对照组和冲击组,对照组给予口服阿法骨化醇0.75μg/d,冲击组给予口服阿法骨化醇3μg/次,2次/周,观察两组患者血清全段甲状旁腺素(iPTH)的变化。结果:对照组血钙水平在治疗第4周较治疗前无明显变化,治疗第8、12周时均较治疗前显著升高,冲击组血钙水平在治疗后较治疗前显著升高;两组血磷治疗前、后比较无明显变化;两组iPTH水平均较治疗前显著降低,冲击组显著低于对照组。结论:阿法骨化醇冲击治疗可以降低血液透析伴继发性甲状旁腺功能亢进患者的iPTH,维持血钙、血磷在正常范围。

作者张苇陈志雄梁玉梅

机构地区湖南省人民医院肾内科中南大学湘雅三医院老年病科

出处《医学理论与实践》 2016年第9期1186-1187,共2页 The Journal of Medical Theory and Practice

关键词慢性肾功能不全继发性甲状旁腺功能亢进阿法骨化醇

分类号 R459.5 [医药卫生—治疗学]

引文网络
相关文献

参考文献7

1Fretz JA,Zella LA,Kim S,et al.1,25-dihydroxyvitamin D3induces expression of the Wnt signaling co-regulator LRP5via regulatory elements located significantly downstream of the gene’s transcriptional start site[J].Steroid Biochem Mol Biol,2007,103(3-5):440-445. 被引量：1
2Schumock GT,Andress DL,Marx SE,et al.Association of secondary hyperparathyroidism with CKD progression,health care costs and survival in diabetic predialysis CKD patients[J].Nephron Clin pract,2009,113(1):c54-61. 被引量：1
3Nikodimopoulou M,Liakos S.Secondary hyperparathyroidism and target organs in chronic kidney disease[J].Hippokratia,2011,15(1):33-38. 被引量：1
4Ketteler M,Rix M,Fan S,et al.Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis[J].Clin J Am Soc Nephrol,2008,3(4):1125-1130. 被引量：1
5牛新,吕放光.骨化三醇防治透析性骨病临床观察[J].现代预防医学,2007,34(4):891-892. 被引量：8
6陈向前,陈维广.阿法迪三治疗规律血液透析患者继发性甲状旁腺功能亢进的临床研究[J].中国血液净化,2005,4(6):334-335. 被引量：5
7张建荣.骨化三醇注射液治疗继发性甲状旁腺功能亢进的研究进展[J].中国血液净化,2011,10(2):114-115. 被引量：13

二级参考文献25

1Ito H,Ogata H,Yamamoto M,et al.Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism:a randomized,crossover trial[J].Clin Nephrol,2009,71:660-668. 被引量：1
2National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J].Am J Kidney Dis,2003,42:S1-201.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis.2003:42(4 Suppl 3):S1-201. 被引量：1
3Levey AS,Coresh J,Balk E.et al.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Ann Intern Med,2003,139:137-147. 被引量：1
4Raggi P,Boulay A,Chasan-Taber S,et al.Cardiac calcification in adult hemodialysis patients.A link between end-stage renal disease and cardiovascular disease?[J].J AM COLL Cardiol,2002,39:695-701. 被引量：1
5Andress DL,Norris KC,Coburn JW,et al.Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure[J].N Engl J Med,1989,321:274-279. 被引量：1
6Chan R,Gleun GW,De Vita MV,et al.Effect of oral vs intravenous colcitriol on serum parathyroid hormone levels in chronic hemodialysis patients[J].Nephrol Dial Transplant,1993,22:736-745. 被引量：1
7Borazan A,Ustun H,Cefle A,et al.Comparatire efficacy of oral and intrayenous calcitriol treatment in haemodialysis patients:effects on serum biochemistry and cytokine levels[J].J Int Med Res,2003,31:489-496. 被引量：1
8Tang M,Wolf M,Ofsthun MN,et al.Activated injectable vitamin D and hemodialysis survival:a historical cohort study[J].J Am Soc Nephrol,2005,16:1115-1125. 被引量：1
9E11iott J,Mishier D,Agarwal R.Hyporesponsiveness to erythropoietin:causes and management[J].Adv Chronic Kidney Dis,2009,16:94-100. 被引量：1
10Valderrabano F,Jones EH,Mallick NP.Report on management of renal failure in Europe,XXIV,1993[J].Nephrol Dial Transplant,1995,10 Suppl 5:1-25. 被引量：1